XML 72 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
License Agreement - Additional Information (Details) - License Agreement - USD ($)
 1 Months Ended 12 Months Ended
Feb. 29, 2020
Feb. 28, 2019
Dec. 31, 2021
Dec. 31, 2020
Schedule Of License Agreement [Line Items]        
Upfront payment upon execution of agreement   $ 25,000    
Upfront payment within first anniversary of license agreement   225,000    
Written notice period for termination of agreement     90 days  
Termination period Description     WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.  
Investigation New Drug (IND)        
Schedule Of License Agreement [Line Items]        
Expected milestone payment on achieving certain regulatory and commercial milestones     $ 125,000  
Milestone payment     0  
Royalty payments     0  
Investigation New Drug (IND) | Maximum        
Schedule Of License Agreement [Line Items]        
Expected milestone payment on achieving certain regulatory and commercial milestones     17,500,000  
Investigation New Drug (IND) | Minimum [Member]        
Schedule Of License Agreement [Line Items]        
Expected royalty payments upon first commercial product sale     100,000  
Initial Closing of Series A Preferred Stock        
Schedule Of License Agreement [Line Items]        
Payment for upfront fee $ 225,000      
Research and Development        
Schedule Of License Agreement [Line Items]        
Payment for upfront fee   $ 250,000    
General and Administrative Expenses        
Schedule Of License Agreement [Line Items]        
Legal patent fees     $ 100,000  
General and Administrative Expenses | Maximum        
Schedule Of License Agreement [Line Items]        
Legal patent fees       $ 100,000